Respiri Limited
RSHUF
Other OTC0.06
USD
- -
- -
ISIN
AU000000RSH4
Return %
Stock
S&P500
1Y
3,773.33
26.53
3Y
19.79
76.60
5Y
16.20
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Marjan Mikel
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 432 St Kilda Road Melbourne VIC Australia 3004
- IPO Date
- Jun 1, 2011
- Website
- respiri.co
- Similar Companies
- Business
- Respiri Limited Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an Australian e-Health SaaS company that develops and commercializes medical devices and digital health platforms for respiratory disease management and chronic care, primarily targeting the US healthcare market with remote patient monitoring (RPM) and chronic care management programs eligible for Current Procedural Terminology (CPT) code reimbursement. Its core products and services include the FDA-approved Class II medical device wheezo®, a world-first wheeze detector that analyzes breath sounds and integrates with the respiriTM mobile app and Respiri health portal to track symptoms, triggers, medication use, and weather conditions while enabling data sharing with physicians and caregivers; customizable RPM and chronic care management programs for asthma, chronic obstructive pulmonary disorder (COPD), cardiovascular conditions, diabetes, and obesity; and supporting technologies such as the in-development wearable Sorfe for nocturnal monitoring and hospital transition care. The company serves healthcare organizations, physicians, accountable care organizations, health plans, and providers, with operations spanning Australia, the United States (including New York City and Miami offices), and development resources in the Philippines. Founded in 2006 and headquartered at Level 9, 432 St Kilda Road, Melbourne, Victoria, Respiri Limited focuses on reducing hospital admissions and healthcare costs through objective airway limitation measurement and data-driven interventions for chronic respiratory and related diseases affecting hundreds of millions globally. Recent developments include the January 2025 completion of the acquisition of Orb Health Inc., a US-based connected care company, for US$9 million to accelerate US commercialization, achieve operational cost savings, enhance service offerings, and expand the customer base in chronic care; a May 2023 agreement to acquire Access Managed Services LLC, a US RPM provider, alongside a A$6.5 million capital raise; a September 2024 partnership contract between Respiri and Ceras with Covenant Health; a March 2025 A$4 million placement and proposed name change reflecting evolution to a full-service care management leader; and a January 2025 rebranding transition to Vitasora Health Limited while retaining ASX:RSH and OTCQB:RSHUF tickers.